At Sonnet BioTherapeutics, we are taking the fight directly to cancer. Our proprietary FHAB™ (Fully Human Albumin Binding) technology empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.
About Sonnet BioTherapeuticsThis short video provides a visual explanation of the unique mechanism of action of Sonnet’s FHAB platform.
Our FHAB platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.
Technology Platform
Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates.
Pipeline
The Sonnet team combines technical expertise in cytokine biology, as well as extensive experience in drug discovery and development.
TeamStay informed and receive company updates straight to your inbox.
